244 related articles for article (PubMed ID: 32636154)
1. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
[TBL] [Abstract][Full Text] [Related]
2. Gene Polymorphisms Affecting Erectile Dysfunction.
Mostafa T; Taymour M
Sex Med Rev; 2020 Oct; 8(4):561-572. PubMed ID: 32169432
[TBL] [Abstract][Full Text] [Related]
3. Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight.
Mostafa T; Alghobary MF
Sex Med Rev; 2022 Jul; 10(3):392-402. PubMed ID: 34903486
[TBL] [Abstract][Full Text] [Related]
4. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
5. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
Mostafa T; Alghobary M; Hanafy NS; Abosief A
Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis.
Mykoniatis I; Pyrgidis N; Sokolakis I; Ouranidis A; Sountoulides P; Haidich AB; van Renterghem K; Hatzichristodoulou G; Hatzichristou D
JAMA Netw Open; 2021 Feb; 4(2):e2036337. PubMed ID: 33599772
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or combination in treating erectile dysfunction: A systematic review and meta-analysis of randomised controlled trials.
Xu Z; Liu C; Liu S; Zhou Z
Andrologia; 2021 May; 53(4):e14007. PubMed ID: 33587304
[TBL] [Abstract][Full Text] [Related]
8. Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis.
Stridh A; Pontén M; Arver S; Kirsch I; Abé C; Jensen KB
JAMA Netw Open; 2020 Mar; 3(3):e201423. PubMed ID: 32196105
[TBL] [Abstract][Full Text] [Related]
9. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
Basal S; Wambi C; Acikel C; Gupta M; Badani K
BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
[TBL] [Abstract][Full Text] [Related]
10. PDE5A Polymorphisms Influence on Sildenafil Treatment Success.
Marchal-Escalona C; Herrera-Imbroda B; Clemente-Postigo M; Alcaide-Torres J; Quiñonero A; Marchal M; Queipo-Ortuño MI; Aragón IM; Martín-Morales A; Lara MF; Cardona F
J Sex Med; 2016 Jul; 13(7):1104-10. PubMed ID: 27235284
[TBL] [Abstract][Full Text] [Related]
11. Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction.
Khan S; Amjad A; Rowland D
J Sex Med; 2019 Feb; 16(2):300-306. PubMed ID: 30770073
[TBL] [Abstract][Full Text] [Related]
12. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
[TBL] [Abstract][Full Text] [Related]
13. Study of the risk factors of erectile dysfunction and phospho diestrase type 5 inhibitors usage among Egyptian population with erectile dysfunction: A cross-sectional survey.
Elnaser Mohamed TA; Kamel II; Abdelaal AMA; Mohammad AF; GamalEl Din SF
Rev Int Androl; 2021; 19(4):249-258. PubMed ID: 33773939
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of the psychosocial outcomes associated with erectile dysfunction: does the impact of erectile dysfunction extend beyond a man's inability to have sex?
McCabe MP; Althof SE
J Sex Med; 2014 Feb; 11(2):347-63. PubMed ID: 24251371
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
16. Avanafil - a further step to tailoring patient needs and expectations.
Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
20. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
